HIV in Pregnancy: Management
Background
Universal antenatal HIV screening (opt-out testing, repeated for high-prevalence areas or ongoing risk) combined with effective combination antiretroviral therapy (ART) has reduced UK mother-to-child (vertical) transmission of HIV to well under 1% where viral suppression is achieved and guidance is followed. Management is multidisciplinary — obstetrician, HIV physician, specialist midwife, and paediatrician — and is individualised around achieving and maintaining an undetectable viral load well before delivery.
Antiretroviral Therapy in Pregnancy
- All pregnant women/people living with HIV should be established on combination ART, which is continued after birth and lifelong (not stopped postpartum), regardless of CD4 count.
- For those not already on treatment at conception, a standard first-line combination is a two-drug NRTI backbone — tenofovir plus emtricitabine, or abacavir plus lamivudine — with a third agent, commonly dolutegravir, reflecting its potency, tolerability, and the extensive reassuring pregnancy safety data now available (surveillance of over 14,000 conception exposures has not shown an increased risk of neural tube defects, the earlier signal that had prompted caution).
- The goal is a plasma viral load that is undetectable (<50 copies/mL) well in advance of delivery; ART should be started early enough in pregnancy (or continued, if already on treatment) to achieve this.
- Women already stable on effective ART pre-conception should generally continue their existing regimen if it is safe and effective in pregnancy, rather than switching unnecessarily.
Mode of Delivery: Viral Load-Based Decision
Mode of delivery is determined primarily by the viral load closest to delivery (ideally checked at around 36 weeks):
- Viral load <50 copies/mL: planned vaginal delivery is supported in the absence of other obstetric contraindications; caesarean section is not required for HIV indication alone.
- Viral load 50–399 copies/mL: transmission risk is higher and not fully characterised at this range — planned caesarean section is generally recommended, individualised with the multidisciplinary team.
- Viral load ≥400 copies/mL, or unknown/unavailable close to delivery: planned caesarean section should be arranged to minimise vertical transmission risk.
- Where a planned caesarean is indicated for HIV, it is scheduled electively at 38+0–39+0 weeks — later than a standard elective caesarean, but still ahead of spontaneous labour, to reduce the chance of rupture of membranes or labour starting first.
- Intrapartum interventions that increase infant exposure to maternal blood (fetal scalp electrodes, fetal blood sampling, instrumental birth, early amniotomy) should be avoided where the viral load is not confirmed undetectable.
Neonatal Post-Exposure Prophylaxis (PEP)
- All infants born to mothers with HIV receive postnatal antiretroviral prophylaxis, started as soon as possible after birth and no later than 4 hours.
- Low/very-low risk infants (maternal viral load reliably <50 copies/mL on ART throughout pregnancy): zidovudine monotherapy, for a shorter course (as short as 2 weeks in very-low-risk infants).
- Higher-risk infants (detectable maternal viraemia, late-diagnosed or untreated maternal HIV, or other risk factors): three-drug combination prophylaxis — typically zidovudine and lamivudine for 4 weeks, with nevirapine added for the first 2 weeks.
- Infants unable to tolerate oral prophylaxis (e.g. extreme prematurity, risk of necrotising enterocolitis) may be given intravenous ART.
- All exposed infants undergo scheduled HIV PCR testing in infancy to confirm their status.
Infant Feeding
- Historically, exclusive formula feeding was the default UK recommendation for women with HIV.
- BHIVA's 2025 guidance now supports shared decision-making: women/birthing parents on ART with a sustained undetectable viral load (<50 copies/mL) who wish to breastfeed should be counselled that a small residual transmission risk persists, and supported to do so with enhanced monitoring — monthly maternal and infant HIV viral load testing during breastfeeding and for two months after stopping.
- Breastfeeding should be stopped, and the infant reviewed urgently, if maternal viral load rises above 50 copies/mL, or if there is mastitis, cracked nipples, or infant/maternal gastrointestinal illness — all of which increase transmission risk.
- Formula feeding remains an appropriate and fully supported choice for any woman who prefers it.
High-Yield Exam Points
- GTG39 is archived; current UK practice follows BHIVA's 2025 pregnancy and postpartum HIV guidelines.
- Universal opt-out antenatal HIV screening underpins the whole prevention pathway.
- Lifelong combination ART for all pregnant women with HIV, aiming for viral load <50 copies/mL before delivery.
- Mode of delivery by viral load near delivery: <50 → vaginal delivery supported; 50–399 → caesarean generally recommended; ≥400 or unknown → planned caesarean section.
- HIV-indicated elective caesarean is timed at 38+0–39+0 weeks.
- Avoid fetal scalp electrodes, fetal blood sampling, and instrumental delivery unless viral load is confirmed undetectable.
- Neonatal PEP: zidovudine monotherapy for low-risk infants; triple-drug prophylaxis (zidovudine + lamivudine 4 weeks, nevirapine 2 weeks) for higher-risk infants; start within 4 hours of birth.
- Infant feeding is now a shared decision — undetectable viral load on ART does not mandate formula feeding, but breastfeeding requires enhanced monthly monitoring and immediate cessation if viral load rises or risk factors (mastitis, cracked nipples, infant illness) occur.
Source: RCOG Green-top Guideline No. 39 (Archived — superseded by the *BHIVA Guidelines on the Management of HIV in Pregnancy and the Postpartum Period 2025*, published by the British HIV Association; BHIVA has held clinical authority on this topic for UK practice since well before RCOG formally archived GTG39) (GTG39 3rd edition was published December 2010 (with a 2013 patient information update); the current governing document is BHIVA's 2025 guideline (published June 2025, following a 2024 public consultation))
Read the original on rcog.org.uk
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).